Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.
Rangwala F, Zafar SY, Abernethy AP.
Curr Opin Support Palliat Care · review; journal article · DOI 10.1097/spc.0b013e32834f689d PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för fosaprepitant. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
10 träffarFosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH, Herrstedt J.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.11.199Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology.
J Clin Oncol · research-article; systematic review; practice guideline; journal article · DOI 10.1200/jco.2010.34.4614Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.
Expert Rev Pharmacoecon Outcomes Res · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1586/erp.11.47Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J.
J Clin Oncol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2010.31.7859Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on supportive care issues related to lung cancer.
Boehmer L, Waqar S, Butler S, Sezhiyan A, Govindan R.
J Thorac Oncol · conference proceedings · DOI 10.1097/jto.0b013e318200f95dPharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.
Marbury TC, Ngo PL, Shadle CR, Jin B, Panebianco D, Caro L, Valentine J, Murphy G.
J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1177/0091270010387792Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.
Langford P, Chrisp P.
Core Evid · review-article; journal article · DOI 10.2147/ce.s6012Pharmacokinetic evaluation of fosaprepitant dimeglumine.
Colon-Gonzalez F, Kraft WK.
Expert Opin Drug Metab Toxicol · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1517/17425255.2010.513970Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC, Jin B, Panebianco D, Murphy MG, Sun H, Evans JK, Han TH, Constanzer ML, Dru J, Shadle CR.
Anesth Analg · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1213/ane.0b013e3181ac1066